Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rosuvastatin calcium, quantity: 41.6 mg - tablet, film coated - excipient ingredients: purified water; lactose monohydrate; magnesium stearate; microcrystalline cellulose; magnesium oxide; crospovidone; titanium dioxide; hypromellose; triacetin; iron oxide red - crestabs should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events crestabs is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). crestabs is indicated to: ? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia crestabs is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with crestabs, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rosuvastatin calcium, quantity: 41.6 mg - tablet, film coated - excipient ingredients: magnesium stearate; lactose monohydrate; crospovidone; microcrystalline cellulose; magnesium oxide; purified water; titanium dioxide; hypromellose; triacetin; iron oxide red - rosuvastatin pcor should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events rosuvastatin pcor is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvastatin pcor is indicated to: ? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia rosuvastatin pcor is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with rosuvastatin pcor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pharmacor pty ltd - rosuvastatin calcium, quantity: 20.8 mg - tablet, film coated - excipient ingredients: magnesium stearate; magnesium oxide; lactose monohydrate; microcrystalline cellulose; crospovidone; purified water; titanium dioxide; hypromellose; triacetin; iron oxide red - rosuvacor should be used as an adjunct to diet when the response to diet and exercise is inadequate.,prevention of cardiovascular events rosuvacor is indicated for prevention of major cardiovascular events in men ?50 years old and women ?60 years old with no clinically evident cardiovascular disease but with at least two conventional risk factors for cardiovascular disease (hypertension, low hdl-c, smoking, or a family history of premature coronary heart disease). rosuvacor is indicated to: ? reduce the risk of nonfatal myocardial infarction ? reduce the risk of nonfatal stroke ? reduce the risk of coronary artery revascularisation procedures.,in patients with hypercholesterolaemia rosuvacor is indicated for the treatment of hypercholesterolaemia (including familial hypercholesterolaemia). prior to initiating therapy with rosuvacor, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy, alcoholism) should be identified and treated.

Malta - engelsk - Medicines Authority

farmak international sp. z o.o. aleja jana pawla ii 22 00-133 warsaw , poland - film-coated tablet - sitagliptin 25 mg - drugs used in diabetes

Malta - engelsk - Medicines Authority

farmak international sp. z o.o. aleja jana pawla ii 22 00-133 warsaw , poland - film-coated tablet - sitagliptin 50 mg - drugs used in diabetes

Malta - engelsk - Medicines Authority

farmak international sp. z o.o. aleja jana pawla ii 22 00-133 warsaw , poland - film-coated tablet - sitagliptin 100 mg - drugs used in diabetes

Malta - engelsk - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - film-coated tablet - sitagliptin 25 mg - drugs used in diabetes

Malta - engelsk - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - film-coated tablet - sitagliptin 50 mg - drugs used in diabetes

Malta - engelsk - Medicines Authority

galenicum health, s.l.u calle sant gabriel, 50 esplugues de llobregat 08950 barcelona, spain - film-coated tablet - sitagliptin 100 mg - drugs used in diabetes

Malta - engelsk - Medicines Authority

pharmacare srl via marghera, 29 20149, milan, italy - film-coated tablet - sitagliptin 25 mg - drugs used in diabetes